Is RCUS a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Arcus Biosciences (RCUS) rests on Casdatifan carries the whole valuation: Arcus owns casdatifan outright outside the Taiho Territory and leads its global development. The bear case rests on concentration is the central risk. Analysts covering it publish targets from $23.00 to $50.00 against a $15.62 share price on November 20, 2026, so even the professionals disagree by 66% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

RCUS key stats

At $15.62 on November 20, 2026, Arcus Biosciences (RCUS) has a market cap of $2.2B.

Market cap
$2.2B
Price to book
5.6
Beta
1.09

Market cap, P/E and yield are measured at the $15.62 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Arcus Biosciences (RCUS)?

The last two weeks for Arcus Biosciences, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • RCUS closed at $15.62 on November 20, 2026, down 10.4% over the past five trading days (from $17.43).

Arcus Biosciences filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Arcus runs a single reportable segment out of Hayward, California with roughly 600 employees, and it has never generated revenue from product sales. Every dollar recognized since the 2018 IPO has come from research, collaboration and license arrangements, principally with Gilead Sciences and Japan's Taiho Pharmaceutical. Gilead paid $725 million in 2022 to license the anti-TIGIT program (domvanalimab and AB308), the adenosine receptor program (etrumadenant) and the CD73 program (quemliclustat), plus a further $100 million option continuation payment received in 2024. Taiho holds rights across Japan and much of Asia excluding China to five Arcus programs, exercised its casdatifan option in the fourth quarter of 2025 for $15 million, and became obligated in the second quarter of 2026 to pay a $30 million clinical milestone tied to the Phase 3 PEAK-1 study. Those payments sit in deferred revenue and are released to the income statement as Arcus performs the underlying research, so reported revenue tracks the pace of laboratory and trial work rather than any commercial activity. The portfolio itself has narrowed sharply. Gilead returned the etrumadenant license in 2025, three Phase 3 studies of domvanalimab have been stopped since December 2025, and casdatifan, which Arcus owns outright, is what remains. What the market is paying for sits in one indication. Casdatifan is an oral HIF-2alpha inhibitor for clear cell renal cell carcinoma, a class in which Merck's belzutifan is the only approved drug, and Arcus leads global development while working through regional partners. PEAK-1, a Phase 3 comparing casdatifan plus cabozantinib against cabozantinib alone in patients who have already had immunotherapy, is expected to complete enrollment by the end of 2026, and a second registrational study, PEAK-20, in first-line disease with nivolumab and ipilimumab, is meant to start in the same window. Management has publicly framed the commercial opportunity at $5 billion to $10 billion. The reported numbers move the other way: revenue fell 74% year over year in the second quarter to $41 million and to ~$9 million in the third quarter, the trailing twelve-month net loss is ~$453 million, and cash plus marketable securities dropped from $1.01 billion at the end of 2025 to $775 million at June 30, 2026 and to roughly ~$630 million at September 30 on Yahoo Finance's basis. The third-quarter net loss was ~$128 million, or ~$1.00 per share, wider than the ~$0.89 consensus. The company guides to roughly $600 million at year-end 2026 and to a runway lasting into at least the second half of 2028, which places its next financing decision after the data that will define the asset.

The bull case: what would have to be true for $50.00

The most optimistic published target on RCUS is $50.00, +220.1% from the $15.62 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Casdatifan carries the whole valuation

Arcus owns casdatifan outright outside the Taiho Territory and leads its global development. The near-term calendar is dense. An ARC-20 data package was presented at an investor event in New York on October 20, 2026, covering initial first-line efficacy for casdatifan plus zimberelimab, mature objective response rate and first progression-free survival data from the second-line casdatifan plus cabozantinib cohort (roughly 45 patients with at least 18 months of follow-up), and overall survival updates from the late-line monotherapy cohorts. The shares fell through the weeks that followed, ending November 20 about ~15% lower over the month and ~50% lower over three months, so the market has marked the asset down even as its development calendar held. PEAK-1 should finish enrolling by year end and PEAK-20 is scheduled to begin in the same window. A Nature publication tied deep and sustained suppression of serum erythropoietin to higher response rates and longer progression-free survival, the mechanistic case Arcus makes for potency against belzutifan. Management sizes the opportunity at $5 billion to $10 billion.

2. Gilead has stepped back without selling

Gilead's option rights over the broader Arcus pipeline ended on July 14, 2026 after Gilead declined to make the option continuation payment, so the CCR6, CD89 and CD40L programs are no longer promised to anyone. On August 5, 2026 the two companies signed a new investor rights agreement under which Gilead gave up its right to designate directors. Dietmar Berger, Johanna Mercier and Linda Higgins all resigned from the board that day, and the board shrank from eleven seats to eight. Gilead still held approximately 24.7% of the shares (31,424,760) at June 30, 2026 and keeps existing licenses to domvanalimab, AB308, quemliclustat and zimberelimab, plus time-limited options on AB801, AB598 and a TNF inhibitor. The stake stays; the influence does not.

3. The TIGIT program is finished, and spending is coming down with it

Three Phase 3 studies of domvanalimab have been stopped in nine months: STAR-221 in December 2025 after an interim analysis showed no benefit over standard of care, STAR-121 in April 2026 for futility, and the AstraZeneca-partnered PACIFIC-8 in August 2026. R&D expense fell to $113 million in the second quarter of 2026 from $139 million a year earlier, and to $235 million for the half from $261 million. The segment disclosure shows where the money went out: early-stage and preclinical spend halved to $39 million for the half from $80 million, while late-stage program spend eased to $111 million from $129 million. Management expects R&D to keep declining near term as the domvanalimab studies wind down, offset partly by heavier casdatifan and immunology investment.

4. The balance sheet is funded past the decisive data

Cash and marketable securities stood at $775 million on June 30, 2026 against $198 million of current liabilities and $101 million of long-term debt. Operating cash use was $257 million in the first half, roughly flat against $265 million a year earlier, and Yahoo Finance shows cash and investments near ~$630 million at September 30, 2026 against ~$241 million of total debt and lease obligations, on track for the company's ~$600 million year-end guide. The Hercules facility runs to $250 million in four tranches, of which $100 million is drawn; it matures in September 2030 and is interest-only until at least September 2028, and two of the remaining $50 million tranches become available only on clinical or regulatory milestones. An equity distribution agreement permits up to $200 million of at-the-market sales. Arcus already used the equity market hard in 2025, issuing 29.4 million shares across two underwritten offerings for approximately $438 million gross. The share count has gone from 92.2 million at the end of 2024 to 127.3 million on July 30, 2026.

The bear case: what would have to be true for $23.00

The most pessimistic published target is $23.00, +47.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Arcus Biosciences is worth if the risks below bite instead of the drivers above.

Concentration is the central risk. Three Phase 3 domvanalimab studies read out badly inside nine months, and Arcus itself warns in the filing that Phase 2 results were not predictive: EDGE-Gastric showed median overall survival beyond two years against Phase 3 benchmarks of 13 to 14 months, yet STAR-221 was still stopped in December 2025 for no benefit over standard of care. The same caution attaches to reading ARC-20 across into PEAK-1 and PEAK-20, and the ~50% fall in the shares over the three months to November 20, 2026 shows how far the market will reprice a single-asset company around one data event. Competitively, casdatifan enters a class Merck already occupies with belzutifan, which carries approval, a sales force and years of prescriber familiarity. On the financial side the revenue line is mechanically shrinking: deferred revenue fell to $56 million at June 30, 2026 from $78 million at year end and $319 million two years before, and partnership reimbursements that offset R&D dropped to $36 million for the half from $71 million, so reported expense can worsen even where gross spending falls. The Hercules loan is secured by substantially all of the company's assets and carries a minimum cash covenant beginning in July 2027, conditionally waived only if market capitalization exceeds a specified threshold, tying a financing covenant to the share price at the moment a data disappointment would bite hardest; the market value has already fallen from roughly $3.9 billion in August to about ~$2.3 billion. Gilead's ~24.7% position is registered and no longer accompanied by board seats, removing one reason for it to sit still. The $200 million at-the-market program and the 29.4 million shares issued during 2025 show how this company funds itself. Accumulated deficit reached $1.704 billion at June 30, 2026, the IRS is examining the 2023 tax year, and standard-of-care comparators including cabozantinib, carboplatin and oxaliplatin are flagged in the filing as difficult to source for trials.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RCUS already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on RCUS

12 analysts cover RCUS, with an average target of $40.92 (+162.0% against $15.62) and a split of 13 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RCUS forecast and price target page.

How is RCUS valued?

Market cap, P/E and dividend yield at today's price are in the RCUS key stats above. The business figures below come from Arcus Biosciences's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$100 million for the twelve months to September 30, 2026, versus $247 million in fiscal 2025 and $258 million in fiscal 2024. All of it is collaboration revenue from Gilead and Taiho; Arcus has never recorded product sales. Third-quarter 2026 revenue was ~$9 million, down ~65% from a year earlier, after $41 million in the second quarter (down 74%) and $17 million in the first.
  • 2026 guidance and the deferred revenue behind it: Management guides GAAP revenue of $65 million to $75 million for full-year 2026, which would be roughly a 70% decline from 2025; ~$67 million had been recognized through September, so the guide implies a small fourth quarter, and consensus is ~$6 million. The deferred revenue balance that feeds the line stood at $56 million at June 30, 2026 ($19 million current and $37 million noncurrent), down from $78 million at December 31, 2025 and $319 million at December 31, 2024. Remaining performance obligations were disclosed at $256 million at the end of 2025.
  • Operating expenses: R&D was $113 million in the second quarter of 2026 and $235 million for the half, down from $139 million and $261 million. G&A was $24 million and $53 million against $29 million and $57 million. Full-year 2025 R&D was $523 million and G&A $110 million. Partnership reimbursements offsetting R&D fell to $36 million for the half from $71 million, and late-stage program spend came in at $111 million versus $129 million.
  • Earnings and EPS: Net loss of $91 million, or $0.72 per share, in the second quarter of 2026, and $219 million, or $1.74 per share, for the first half on 125.7 million weighted-average shares. The third-quarter 2026 loss was ~$128 million, or ~$1.00 per share. The trailing twelve-month loss is ~$453 million, or ~$3.64 per share. Fiscal 2025 produced a $353 million loss and fiscal 2024 a $283 million loss. Accumulated deficit stands at $1.704 billion. No P/E ratio exists and no income tax was recorded, given forecast full-year net operating losses.
  • Latest quarter versus estimates: The third-quarter 2026 loss of ~$1.00 per share, reported November 4, was wider than the ~$0.89 consensus, on ~$9 million of revenue. That followed a second-quarter loss of $0.72 that was narrower than the ~$0.81 expected and a first-quarter loss of $1.02 that was wider than the ~$0.83 expected. Consensus for the fourth quarter is a ~$0.86 loss per share.
  • Cash flow and balance sheet: Cash, cash equivalents and marketable securities of $775 million at June 30, 2026, made up of $150 million cash, $552 million current marketable securities and $73 million long term, down from $1.01 billion at December 31, 2025. Operating cash use was $257 million in the first half. Total assets were $924 million, current liabilities $198 million, long-term debt $101 million under the Hercules facility maturing September 2030, and stockholders' equity $464 million. Guidance is ~$600 million of cash at year-end 2026 and runway into at least the second half of 2028. Yahoo Finance shows cash and investments near ~$630 million and total debt near ~$241 million at September 30, 2026.
  • Market pricing: The shares closed near $15.80 on November 20, 2026, against a 52-week range of roughly $15.63 to $31.74, giving a market capitalization near $2.3 billion. That is down from around $30 in late August, ~50% lower over three months, ~15% lower over one month, ~32% lower year to date and ~26% lower over one year. Enterprise value is roughly $1.9 billion once ~$630 million of September 30 cash and ~$241 million of debt are netted. There is no P/E, no EV/EBITDA and no dividend, since the company loses money at the operating line. Gilead's ~24.7% holding means the tradeable float is materially smaller than the headline share count. The mean analyst target across 12 analysts is about $41, far above the share price.

As of November 2026: Every conventional multiple here is either undefined or misleading. The ~23x trailing sales figure a screener prints at the November 20, 2026 price rests on a revenue stream management has already guided down to $65 million to $75 million for 2026, with no commercial engine behind it. The ~$1.9 billion enterprise value instead represents a probability-weighted view of casdatifan in clear cell kidney cancer, a market Arcus sizes at $5 billion to $10 billion, discounted for Phase 3 risk and for the cash the company expects to consume between now and the second half of 2028. That view has moved sharply: the market value fell from roughly $3.9 billion in August to about $2.8 billion ahead of the October 20 ARC-20 event and to about $2.3 billion by November 20, even though JPMorgan (Overweight, $41 target), William Blair (Outperform) and TD Cowen (Buy) had initiated coverage between mid-September and mid-October.

How do you decide if RCUS is a buy?

Whether RCUS is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold RCUS indirectly through an index or sector ETF before adding more.

What would change your mind on RCUS

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Casdatifan carries the whole valuation stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: concentration is the central risk fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RCUS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RCUS against your real portfolio and see your actual exposure before deciding.

Your questions about Arcus Biosciences

Ask Walnut's AI anything about RCUS and see how it fits what you own.

FAQ

Is RCUS a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Casdatifan carries the whole valuation, with revenue (ttm) at ~$100 million for the twelve months to September 30, 2026, versus $247 million in fiscal 2025 and $258 million in fiscal 2024. All of it is collaboration revenue from Gilead and Taiho; Arcus has never recorded product sales. Third-quarter 2026 revenue was ~$9 million, down ~65% from a year earlier, after $41 million in the second quarter (down 74%) and $17 million in the first.. The bear case rests on concentration is the central risk. Analysts covering it are spread from $23.00 to $50.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell RCUS?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Concentration is the central risk. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $23.00, +47.2% from the $15.62 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for RCUS?

+

Casdatifan carries the whole valuation. Arcus owns casdatifan outright outside the Taiho Territory and leads its global development. The most optimistic analyst target on RCUS is $50.00, +220.1% from the $15.62 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for RCUS?

+

Concentration is the central risk. Three Phase 3 domvanalimab studies read out badly inside nine months, and Arcus itself warns in the filing that Phase 2 results were not predictive: EDGE-Gastric showed median overall survival beyond two years against Phase 3 benchmarks of 13 to 14 months, yet STAR-221 was still stopped in December 2025 for no benefit over standard of care. The same caution attaches to reading ARC-20 across into PEAK-1 and PEAK-20, and the ~50% fall in the shares over the three months to November 20, 2026 shows how far the market will reprice a single-asset company around one data event. Competitively, casdatifan enters a class Merck already occupies with belzutifan, which carries approval, a sales force and years of prescriber familiarity. On the financial side the revenue line is mechanically shrinking: deferred revenue fell to $56 million at June 30, 2026 from $78 million at year end and $319 million two years before, and partnership reimbursements that offset R&D dropped to $36 million for the half from $71 million, so reported expense can worsen even where gross spending falls. The Hercules loan is secured by substantially all of the company's assets and carries a minimum cash covenant beginning in July 2027, conditionally waived only if market capitalization exceeds a specified threshold, tying a financing covenant to the share price at the moment a data disappointment would bite hardest; the market value has already fallen from roughly $3.9 billion in August to about ~$2.3 billion. Gilead's ~24.7% position is registered and no longer accompanied by board seats, removing one reason for it to sit still. The $200 million at-the-market program and the 29.4 million shares issued during 2025 show how this company funds itself. Accumulated deficit reached $1.704 billion at June 30, 2026, the IRS is examining the 2023 tax year, and standard-of-care comparators including cabozantinib, carboplatin and oxaliplatin are flagged in the filing as difficult to source for trials. The most pessimistic published target is $23.00, +47.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Arcus Biosciences do?

+

Arcus Biosciences is a clinical-stage oncology company whose revenue comes from Gilead and Taiho collaborations rather than product sales.

What would have to change for RCUS to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Casdatifan carries the whole valuation) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (concentration is the central risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Arcus Biosciences do?

+

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, listed on the New York Stock Exchange under RCUS, with roughly 600 employees and one reportable segment. It designs small molecules and antibodies for cancer and, more recently, for inflammatory and immunological disease. Nothing in the portfolio is approved or sold, so the entire revenue line comes from collaboration and license agreements with Gilead Sciences, Taiho Pharmaceutical and AstraZeneca. The lead asset is casdatifan, an oral HIF-2alpha inhibitor in Phase 3 for clear cell renal cell carcinoma, which Arcus owns outside Japan and much of Asia. Other programs include quemliclustat in pancreatic cancer, licensed to Gilead, and early immunology candidates aimed at MRGPRX2, TNFR1, CCR6, STAT6, CD89 and CD40L.

Why did RCUS stock go up so much?

+

The re-rating tracked the pipeline rather than the income statement. Over the twelve months to August 2026 the shares ran from a low near $9.92 toward a high around $31.74 while revenue fell 74% year over year. Most of that gain has since reversed: by November 20, 2026 the stock was near $15.80, down ~50% over three months through the October 20 data event and the November 4 quarterly report, and ~26% lower than a year earlier. Two things drove it. Casdatifan produced encouraging Phase 1/2 evidence in clear cell kidney cancer, including a Nature paper linking sustained erythropoietin suppression to higher response rates and longer progression-free survival, and Arcus kept full rights to the molecule instead of seeing it optioned away to a partner. At the same time, the failure of three Phase 3 domvanalimab studies removed a distraction and a large share of the spending attached to it. The market marked one asset up while writing another off.

Is Arcus Biosciences profitable?

+

No. Arcus has never generated revenue from product sales and reported a net loss of $91 million, or $0.72 per share, in the second quarter of 2026, plus $219 million for the first half. The third quarter added a ~$128 million loss, or ~$1.00 per share, and the trailing twelve-month loss is roughly $453 million. Fiscal 2025 produced a $353 million loss on $247 million of revenue, and fiscal 2024 a $283 million loss on $258 million. Accumulated deficit reached $1.704 billion by June 30, 2026. One quarter, the second of 2025, came in near break-even, but only because $152 million of previously deferred Gilead and Taiho payments happened to be recognized inside it. Sustained profitability would require an approved and selling product, which the company does not yet have.

Walnut is informational, not investment advice, and gives no verdict on RCUS. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks